

At page 19, line 18, after "f-Met-Leu-Tyr-Tyr" insert--(SEQ ID NO:5)--.

At page 19, line 21, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

At page 19, line 23, after "Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

At page 19, line 25, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

At page 21, line 10, after "f-Met-Leu-Phe-Phe" insert--(SEQ ID NO:2)--.

In the Claims:

41 2. (amended) The pharmaceutical composition of claim 1, wherein said peptide is f-Met-Leu-Phe-Phe (SEQ ID NO:2).

REMARKS

In the Office Action dated June 24, 1999, claims 1-23 are pending, claims 9-23 are withdrawn from consideration, and claims 1-8 are rejected.

Although the office action states that completed copies of forms PTO-1449 are attached, copies of those forms were not attached. applicant requests copies of completed forms PTO-1449 be furnished for Applicant's files.

A "Sequence Listing" as required by 37 C.F.R. § 1.812(c) is submitted herewith including (i) an initial computer readable from (CRF) copy of the "Sequence Listing"; (ii) an initial paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification; and (iii) a statement that the content of the paper and CRF are the same and include no new matter.

The examiner has requested a proof of the power or authority of Mary MacDonald along with a request under 37 CFR §1.42 to issue the patent to her as legal representative of the inventor, John C. Houck. A copy of the appointment of Mary MacDonald as Executrix of the Estate of John C. Houck is enclosed herewith.